echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Hundreds of billions of respiratory diseases drug market, domestic pharmaceutical companies began to exert force!

    Hundreds of billions of respiratory diseases drug market, domestic pharmaceutical companies began to exert force!

    • Last Update: 2020-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Pharmaceutical Network Industry Dynamic: Respiratory disease is a common disease and multiple morbidity, the second largest disease in China, second only to cardiovascular diseaseRespiratory diseases are classified as acute respiratory diseases and chronic respiratory diseasesIndustry insiders have pointed out that 87% of China's total deaths are caused by chronic diseases, with 45% of central cerebrovascular diseases, 23% of cancer (of which lung cancer accounts for the first cause of cancer deaths) and respiratory diseases accounting for 11%And if the life year adjusted by disability is calculated, the greater burden of disease in our country is respiratory disease, followed by cardiovascular diseaseaccording todata, the prevalence rate of respiratory diseases in China is about 6.94 percent, and more than 92 million people in China suffer from respiratory diseases each yearGlobally, respiratory diseases are also a growing global public health problemThe WHO estimates that more than 1 billion people worldwide suffer from respiratory diseases, and that the incidence of respiratory diseases is on the rise in almost all countriesat present, the incidence of respiratory diseases and the rising incidence of a huge market demand for drugs, and thus formed a huge drug market, and the market size is expanding year by yearStatistics show that in 2015, China'srespiratory system drugscale of 124.5 billion yuan, 2017 national respiratory system drug market size has exceeded 133 billion yuan, an annual growth rate of about 4%it is understood that AstraZeneca (AZ), GlaxoSmithKline (GSK), Bollinger Ingham (BI) three multinational pharmaceutical companies are the world's three leading companies in inhalation preparations, the current global respiratory field inhalation preparations of heavy products are basically dominated by the three leading enterprisesSimilarly, more than 90% of the domestic respiratory disease strains market has long been dominated by these three multinational drug companiesData show that in the first half of 2019, three foreign enterprises together accounted for about 69.7% of the market shareAmong them, AstraZeneca's Budined is a larger variety of chronic respiratory inhalation agents, accounting for more than 35% of the market share in domestic sample hospitals in the first half of 2019but in recent years, domestic enterprises in inhalation agents on the technical barriers to breakthrough, more and more local enterprises began to lay out this blue sea marketFor example, in December 2018, the fine-lighted Shamitlotikason powder inhaler was placed on the priority review list and is expected to become the first in the country, and the positive-lighted inhaled Budined mixed suspension will also begin on 7 March 2018many enterprises, it is worth mentioning that since 2013, the health yuan has been continuously layout of the respiratory field, the current inhalation preparations business has gradually entered the harvest periodIn April and September 2019, the health meta-inhalation compound isopropylene bromine ammonium solution and hydrochloric acid zosalbutamine atomized inhalation solution were approved for saleBudined was originally expected to be approved in the first half of 2020, but the outbreak has been delayed and is expected to go on sale after JuneThe industry believes that it may open a new pattern in the domestic inhalation preparations marketin general, in recent years, China has issued a series of policies to encourage generic drugs to improve the quality and speed up the replacement of imported drugsAnd in this context, many domestic pharmaceutical companies have begun to actively lay out the heavy varieties of inhaled preparationsOnce successful, it will be very promising to quickly achieve import substitution, providing doctors in the country with more and better options, but also for more patients with asthma and chronic obstructive pulmonary disease.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.